Vancouver, British Columbia – TheNewswire - June 30, 2026 – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, today announced the appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations. The appointments further strengthen Helix’s executive leadership team as the Company prepares for its planned U.S. securities exchange listing, advances the next stage of development for L-DOS47 through LDOS007, the Company’s planned Phase IB/Randomized Phase II study in first-line non-small cell lung cancer (NSCLC), and continues building the legal, governance and operational infrastructure required to support its next phase of growth.

 

“The next stage of Helix’s evolution demands a different kind of company than the one we were building two years ago,” said Thomas Mehrling, MD, PhD, Chief Executive Officer of the Company. “As we prepare for our planned U.S. securities exchange listing and advance L-DOS47 into its next stage of clinical development, we are deliberately strengthening every part of the organization. From our legal and governance framework to our clinical execution capabilities, we are building the leadership team required to support the next phase of Helix’s growth.”

 

“With the preparation of our base shelf prospectus underway and the auditor review of our second-quarter financials completed, we are executing on a clear capital markets roadmap as we prepare for our planned U.S. securities exchange listing. Helen and David are exceptional additions to Helix. Helen brings decades of experience navigating the legal and governance challenges faced by growing life sciences companies, while David has successfully led complex global oncology programs from planning through execution. Together, they significantly strengthen our ability to deliver on our clinical, corporate and capital markets objectives.”

 

Helen Middleton, BPharm, LPC, General Counsel of Helix BioPharma said, “The most exciting opportunities in biopharma are created when strong science is matched by strong execution. Helix has reached an important point in its evolution, and I look forward to helping build the legal and governance framework that supports the Company’s clinical and corporate ambitions.”

 

David Browning, MBA, Vice President of Clinical Operations added, “The opportunity ahead for Helix is compelling. The Company has built an encouraging clinical foundation for L-DOS47, and I look forward to helping execute its next stage of development with the operational excellence required to bring this program forward, and, ultimately, to patients.”

  

About Helen Middleton

Ms. Middleton brings more than 30 years of experience across pharmacy, law, and the global life sciences industry. A qualified life sciences lawyer and registered clinical pharmacist, she has advised pharmaceutical, biotechnology, and medical technology companies across the product life cycle, including research and development, clinical programs, regulatory strategy, commercialization, licensing, and corporate transactions.

Her career includes senior legal roles with leading international law firms and life sciences companies, including Sidley Austin LLP, Matheson LLP, Mundipharma International, Ipsen, and Abcam. Most recently, she has served as Legal Consultant to Kyowa Kirin International. As General Counsel, Ms. Middleton will oversee Helix’s legal affairs, governance, compliance and strategic transactions, helping support the Company’s continued clinical advancement, corporate development initiatives, and planned U.S. securities exchange listing.

 

About David Browning

Mr. Browning brings more than 30 years of experience leading global clinical development programs across the biotechnology, pharmaceutical, contract research organization, and academic sectors. Throughout his career, Mr. Browning has overseen more than 30 Phase I-III clinical studies, spanning first-in-human studies through regulatory approval, and has built and led global oncology clinical operations teams across North America, Europe, Latin America, South Africa, and the Asia-Pacific region.

 

His experience encompasses a broad range of oncology indications and therapeutic modalities, including immunotherapies, targeted therapies, antibody-drug conjugates, cel therapies, biologics, and small molecules. As Vice President of Clinical Operations, Mr. Browning will lead the operational planning and execution of Helix’s clinical development programs, including LDOS007, while expanding operational capabilities for future pipeline growth.

 

These appointments represent another important milestone in preparing Helix for its next phase of clinical development and capital markets execution, as the Company continues to execute on its strategic objectives to create long-term value for patients and shareholders.

 

About Helix BioPharma

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA™, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

 

Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0). For more information, please visit: https://www.helixbiopharma.com/

 

For more information, please contact:

Helix BioPharma Corp.

789 West Pender Street, Suite 480

Vancouver, BC V6C 1H2

Tel: +1 857 208 7687

Thomas Mehrling, MD, PhD, Chief Executive Officer

corporate@helixbiopharma.com

  

Forward-Looking Statements and Risks and Uncertainties

 

This news release contains forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company’s future business, operations, research and development, including the Company’s activities relating to L-DOS47, LEUMUNA, and GEMCEDA, as well as its activities relating to financing and listing on a U.S. securities exchange. Forward-looking statements can further be identified by the use of forward-looking terminology such as “ongoing”, “estimates”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results.

 

Forward-looking statements are necessarily based on a number of estimates and assumptions that the Company considered appropriate and reasonable as of the date such information is given, including but not limited to the assumptions regarding the implied benefits of the transactions. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, including but not limited to the risk that the Company's assumptions on which its forward-looking statements are based may not be accurate; the ability of the Company to capitalize on the potential benefits of the transactions; and the risk factors disclosed in the Company's periodic reports publicly filed and available on its SEDAR+ profile at www.sedarplus.ca. No assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur. There is no assurance that the proposed transactions will be completed in accordance with its terms or at all. The forward-looking statements contained in this news release are made as of the date of this announcement and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.

   

_________________